Effects of nicotinamide riboside on NAD+ levels, cognition, and symptom recovery in long-COVID: a randomized controlled trial
View on PubMed → | DOI | Publisher
Plain-language summary
Published 2025 in EClinicalMedicine, this work by Wu CY and collaborators tackles a specific question within benefits-focused NMN/NAD+ research.
Key findings reported by the authors
- Human study published in EClinicalMedicine (2025) examining Effects of nicotinamide riboside on NAD+ levels, cognition, and symptom recovery in long-C...
- Provides clinical-grade evidence on NAD+/NMN-related outcomes in human participants
- First author: Wu CY; cited frequently in NMN supplementation discussions
What this means for Malaysian buyers
For readers in Malaysia weighing whether to start or continue NMN supplementation, this paper sits at the moderate end of the evidence spectrum. Moderate-tier evidence usually means a small human trial or a well-designed mouse study; helpful for hypothesis-building but not for hard recommendations. Findings here are most directly relevant to benefits decisions, with secondary relevance to compare. Our editorial methodology weights human placebo-controlled trials above mouse mechanistic work above review articles.